|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.42 USD | -0.46% |
|
-4.55% | -32.17% |
| 14/03 | Progyny issues notice of pendency of settlement of derivative action | RE |
| 13/03 | Surgery Partners, Inc. Names Lloyd Dean to Board of Directors | CI |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Profitability | |||||||||
Return on Assets | 6.61 | 3.24 | 5.98 | 6.18 | 8.61 | ||||
Return on Total Capital | 9.25 | 4.52 | 8.12 | 8.31 | 11.8 | ||||
Return On Equity % | 31.41 | 9.66 | 13.34 | 11.14 | 12.48 | ||||
Return on Common Equity | 31.41 | 9.66 | 13.34 | 11.14 | 12.48 | ||||
Margin Analysis | |||||||||
Gross Profit Margin % | 22.4 | 21.26 | 21.94 | 21.71 | 23.63 | ||||
SG&A Margin | 15.94 | 18.3 | 16.22 | 15.93 | 16.41 | ||||
EBITDA Margin % | 6.72 | 3.17 | 5.92 | 6.05 | 7.6 | ||||
EBITA Margin % | 6.58 | 3.03 | 5.72 | 5.79 | 7.28 | ||||
EBIT Margin % | 6.46 | 2.97 | 5.71 | 5.78 | 7.22 | ||||
Income From Continuing Operations Margin % | 13.14 | 3.86 | 5.7 | 4.66 | 4.54 | ||||
Net Income Margin % | 13.14 | 3.86 | 5.7 | 4.66 | 4.54 | ||||
Net Avail. For Common Margin % | 13.14 | 3.86 | 5.7 | 4.66 | 4.54 | ||||
Normalized Net Income Margin | 4.05 | 1.94 | 3.76 | 3.92 | 5 | ||||
Levered Free Cash Flow Margin | 3.18 | 8.76 | 14.78 | 14.96 | 16.49 | ||||
Unlevered Free Cash Flow Margin | 3.18 | 8.76 | 14.78 | 14.96 | 16.49 | ||||
Asset Turnover | |||||||||
Asset Turnover | 1.64 | 1.75 | 1.68 | 1.71 | 1.91 | ||||
Fixed Assets Turnover | 40.21 | 56 | 50.52 | 40.63 | 30.48 | ||||
Receivables Turnover (Average Receivables) | 4.76 | 4.2 | 4.52 | 4.89 | 5.66 | ||||
Short Term Liquidity | |||||||||
Current Ratio | 2.62 | 2.72 | 3.44 | 2.8 | 2.73 | ||||
Quick Ratio | 2.57 | 2.69 | 3.3 | 2.75 | 2.62 | ||||
Operating Cash Flow to Current Liabilities | 0.26 | 0.5 | 1.02 | 1.06 | 1.04 | ||||
Days Sales Outstanding (Average Receivables) | 76.64 | 86.88 | 80.79 | 74.82 | 64.52 | ||||
Average Days Payable Outstanding | 49.29 | 50.28 | 50.41 | 44.16 | 40.64 | ||||
Long Term Solvency | |||||||||
Total Debt/Equity | 3.43 | 2.05 | 3.5 | 4.57 | 5.37 | ||||
Total Debt / Total Capital | 3.32 | 2 | 3.38 | 4.37 | 5.1 | ||||
LT Debt/Equity | 2.95 | 1.72 | 3.12 | 3.89 | 4.65 | ||||
Long-Term Debt / Total Capital | 2.85 | 1.68 | 3.01 | 3.72 | 4.41 | ||||
Total Liabilities / Total Assets | 29.67 | 30.58 | 26.86 | 30.48 | 30.49 | ||||
EBIT / Interest Expense | - | - | - | - | - | ||||
EBITDA / Interest Expense | - | - | - | - | - | ||||
(EBITDA - Capex) / Interest Expense | - | - | - | - | - | ||||
Total Debt / EBITDA | 0.25 | 0.29 | 0.29 | 0.26 | 0.27 | ||||
Net Debt / EBITDA | -3.17 | -6.92 | -5.26 | -2.85 | -2.77 | ||||
Total Debt / (EBITDA - Capex) | 0.26 | 0.34 | 0.31 | 0.28 | 0.33 | ||||
Net Debt / (EBITDA - Capex) | -3.38 | -7.89 | -5.56 | -3.07 | -3.39 | ||||
Growth Over Prior Year | |||||||||
Total Revenues, 1 Yr. Growth % | 45.17 | 57.19 | 38.34 | 7.22 | 10.4 | ||||
Gross Profit, 1 Yr. Growth % | 60.06 | 49.22 | 42.72 | 6.1 | 20.18 | ||||
EBITDA, 1 Yr. Growth % | 71.88 | -25.86 | 158.46 | 9.56 | 38.64 | ||||
EBITA, 1 Yr. Growth % | 74.6 | -27.62 | 161.25 | 8.46 | 38.82 | ||||
EBIT, 1 Yr. Growth % | 83.06 | -27.83 | 166.42 | 8.48 | 37.84 | ||||
Earnings From Cont. Operations, 1 Yr. Growth % | 41.56 | -53.84 | 104.35 | -12.41 | 7.7 | ||||
Net Income, 1 Yr. Growth % | 41.56 | -53.84 | 104.35 | -12.41 | 7.7 | ||||
Normalized Net Income, 1 Yr. Growth % | 80.22 | -24.65 | 171.12 | 11.79 | 40.85 | ||||
Diluted EPS Before Extra, 1 Yr. Growth % | 40.43 | -54.55 | 106.67 | -8.06 | 14.04 | ||||
Accounts Receivable, 1 Yr. Growth % | 77.83 | 78.41 | 0.75 | -2.71 | -6.39 | ||||
Net Property, Plant and Equip., 1 Yr. Growth % | 6.33 | 19.03 | 82.13 | 6.53 | 85.32 | ||||
Total Assets, 1 Yr. Growth % | 41.01 | 51.64 | 39.34 | -19.76 | 22.29 | ||||
Tangible Book Value, 1 Yr. Growth % | 55.56 | 52.5 | 48.37 | -25.17 | 20.88 | ||||
Common Equity, 1 Yr. Growth % | 50.84 | 49.7 | 46.81 | -23.74 | 22.27 | ||||
Cash From Operations, 1 Yr. Growth % | -28.08 | 208.77 | 134.86 | -5.14 | 17.36 | ||||
Capital Expenditures, 1 Yr. Growth % | 105.3 | 52.23 | 12.43 | 48.33 | 240.61 | ||||
Levered Free Cash Flow, 1 Yr. Growth % | -56.07 | 332.96 | 133.2 | 8.54 | 21.72 | ||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -56.07 | 332.96 | 133.2 | 8.54 | 21.72 | ||||
Compound Annual Growth Rate Over Two Years | |||||||||
Total Revenues, 2 Yr. CAGR % | 47.64 | 51.06 | 47.46 | 21.79 | 8.8 | ||||
Gross Profit, 2 Yr. CAGR % | 56.98 | 54.54 | 45.93 | 23.05 | 12.92 | ||||
EBITDA, 2 Yr. CAGR % | 68.78 | 55.96 | 38.43 | 68.28 | 23.25 | ||||
EBITA, 2 Yr. CAGR % | 71.67 | 58.02 | 37.51 | 68.33 | 22.7 | ||||
EBIT, 2 Yr. CAGR % | 82.81 | 67.21 | 38.67 | 70 | 22.28 | ||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 177.04 | -19.16 | -2.88 | 33.78 | -2.88 | ||||
Net Income, 2 Yr. CAGR % | 177.04 | -19.16 | -2.88 | 33.78 | -2.88 | ||||
Normalized Net Income, 2 Yr. CAGR % | 94.69 | 67.81 | 41.3 | 74.14 | 25.49 | ||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 26.37 | -20.11 | -3.08 | 37.84 | 2.39 | ||||
Accounts Receivable, 2 Yr. CAGR % | 69.1 | 78.12 | 34.07 | -0.99 | -4.57 | ||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 104.01 | 12.5 | 47.24 | 39.29 | 40.5 | ||||
Total Assets, 2 Yr. CAGR % | 54.28 | 46.23 | 45.36 | 5.74 | -0.94 | ||||
Tangible Book Value, 2 Yr. CAGR % | 54.69 | 54.02 | 50.42 | 5.37 | -4.89 | ||||
Common Equity, 2 Yr. CAGR % | 48.45 | 50.27 | 48.25 | 5.81 | -3.44 | ||||
Cash From Operations, 2 Yr. CAGR % | 311.99 | 49.02 | 169.29 | 49.26 | 5.51 | ||||
Capital Expenditures, 2 Yr. CAGR % | -15.13 | 76.79 | 30.83 | 29.14 | 124.77 | ||||
Levered Free Cash Flow, 2 Yr. CAGR % | 19.33 | 50.53 | 217.75 | 59.1 | 14.94 | ||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 19.52 | 50.53 | 217.75 | 59.1 | 14.94 | ||||
Compound Annual Growth Rate Over Three Years | |||||||||
Total Revenues, 3 Yr. CAGR % | 68.1 | 50.75 | 46.69 | 32.6 | 17.87 | ||||
Gross Profit, 3 Yr. CAGR % | 79.36 | 54.35 | 50.5 | 31.22 | 22.09 | ||||
EBITDA, 3 Yr. CAGR % | 177.81 | 28.3 | 84.56 | 28.05 | 57.76 | ||||
EBITA, 3 Yr. CAGR % | 156.5 | 28.73 | 86.85 | 27.05 | 57.85 | ||||
EBIT, 3 Yr. CAGR % | 110.81 | 34.11 | 95.3 | 27.77 | 58.52 | ||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 134.26 | 52.45 | 10.12 | -6.17 | 24.45 | ||||
Net Income, 3 Yr. CAGR % | 363.38 | 52.45 | 10.12 | -6.17 | 24.45 | ||||
Normalized Net Income, 3 Yr. CAGR % | 68.29 | 41.88 | 96.14 | 30.69 | 62.25 | ||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -12.94 | -10.13 | 9.67 | -4.77 | 29.4 | ||||
Accounts Receivable, 3 Yr. CAGR % | 79.35 | 72.15 | 47.31 | 20.48 | -2.83 | ||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 154.77 | 70.47 | 32.1 | 32.18 | 53.2 | ||||
Total Assets, 3 Yr. CAGR % | 105.39 | 53.4 | 43.9 | 19.24 | 10.99 | ||||
Tangible Book Value, 3 Yr. CAGR % | 29.25 | 53.96 | 52.12 | 19.19 | 10.3 | ||||
Common Equity, 3 Yr. CAGR % | 38.34 | 48.86 | 49.11 | 18.78 | 11.04 | ||||
Cash From Operations, 3 Yr. CAGR % | 125.46 | 274.23 | 73.42 | 90.18 | 37.76 | ||||
Capital Expenditures, 3 Yr. CAGR % | 54.35 | 3.12 | 52.03 | 36.42 | 78.43 | ||||
Levered Free Cash Flow, 3 Yr. CAGR % | 43.72 | 83.36 | 74.18 | 122.12 | 45.51 | ||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 42.14 | 83.56 | 74.18 | 122.12 | 45.51 | ||||
Compound Annual Growth Rate Over Five Years | |||||||||
Total Revenues, 5 Yr. CAGR % | - | 74.54 | 59.52 | 38.42 | 30.17 | ||||
Gross Profit, 5 Yr. CAGR % | - | 86.58 | 65.16 | 40.97 | 34.16 | ||||
EBITDA, 5 Yr. CAGR % | - | 21.43 | 110.25 | 43 | 57.04 | ||||
EBITA, 5 Yr. CAGR % | - | 20.19 | 99.88 | 43.31 | 57.92 | ||||
EBIT, 5 Yr. CAGR % | - | 16.23 | 78.29 | 47.45 | 61.94 | ||||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | 19.5 | 64.72 | 44.69 | 4.72 | ||||
Net Income, 5 Yr. CAGR % | - | 19.51 | 148.02 | 44.69 | 4.72 | ||||
Normalized Net Income, 5 Yr. CAGR % | - | 14.43 | 57.28 | 53.62 | 64.05 | ||||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | -33.87 | -9.12 | 6.64 | 6.7 | ||||
Accounts Receivable, 5 Yr. CAGR % | - | 84.03 | 59.64 | 37.98 | 23.83 | ||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | 91.25 | 104.59 | 57.24 | 35.4 | ||||
Total Assets, 5 Yr. CAGR % | - | 73.08 | 78.87 | 32.19 | 23.93 | ||||
Tangible Book Value, 5 Yr. CAGR % | - | 26.02 | 37.33 | 32.29 | 26.06 | ||||
Common Equity, 5 Yr. CAGR % | - | 31.02 | 42.22 | 29.86 | 25.32 | ||||
Cash From Operations, 5 Yr. CAGR % | - | 53.37 | 142.06 | 159.09 | 42.16 | ||||
Capital Expenditures, 5 Yr. CAGR % | - | 39.57 | 44.47 | 12.83 | 77.77 | ||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | 97.4 | 73.24 | 47.5 | ||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | 96.09 | 73.35 | 47.5 |
- Stock Market
- Equities
- PGNY Stock
- Financials Progyny, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















